Trial Profile
A study investigating clinical behavior and changes in total and free immunoglobulin E after omalizumab treatment in patients with severe asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Therapeutic Use
- 04 Jan 2017 New trial record